ReviewJournal for immunotherapy of cancer2022
Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages.
Review in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 36 citations in OpenAlex.
- Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids.Oncoimmunology · 2026Article
- A bibliometric analysis of research trends and hotspots regarding macrophage polarization in lung cancer.Journal of thoracic disease · 2026Article
- Biomaterial-guided macrophage modulation: Therapeutic engineering of immune microenvironments.Trends in immunology · 2026Review
- CD13 identifies S100A4Biology direct · 2026Article
- Breast Cancer Milieu Maneuvers Cancer-Associated Macrophages to Synergize Neoplastic Repertoires.Cancers · 2026Review
- Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies.Journal of hematology & oncology · 2026Review
- Mechanistic Research on the Crosstalk Between Macrophage Polarization and Energy Metabolic Reprogramming in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Review
- Exploring macrophage polarization: biological insights, key laboratory techniques and research perspectives.Frontiers in immunology · 2026Review
- Article
- Graphene and Its Derivatives as Modulators of Macrophage Polarization in Cutaneous Wound Healing.Cells · 2025Review
- Equine monocyte-derived macrophages revisited: isolation and comprehensive characterization of pro- versus anti-inflammatory polarisation.The veterinary quarterly · 2025Article
- Article
- Immunomodulatory Natural Products in Cancer Organoid-Immune Co-Cultures: Bridging the Research Gap for Precision Immunotherapy.International journal of molecular sciences · 2025Review
- Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells.Bioconjugate chemistry · 2025Article
- Periprostatic Adipose Tissue as a Contributor to Prostate Cancer Pathogenesis: A Narrative Review.Cancers · 2025Review
- Therapeutic targeting of tumour-associated macrophage receptors.Immunotherapy advances · 2025Review
- Review
- Monitoring Macrophage Polarization with Gene Expression Reporters and Bioluminescence Phasor Analysis.Chemical & biomedical imaging · 2024Article
- Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization.Cell reports. Medicine · 2024Article
- Macrophage manufacturing and engineering with 5'-Cap1 and N1-methylpseudouridine-modified mRNA.Molecular therapy. Methods & clinical development · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophages are the immune cells that accumulate the most in the majority of established tumors and this accumulation is associated with a poor prognosis. Tumor-associated macrophages (TAMs) produce inflammatory cytokines and growth factors that promote tumor expansion and metastasis. TAMs have recently emerged as targets of choice to restore an efficient antitumor response and to limit tumor growth. Many molecules targeting TAMs are actually evaluated in clinical trials, alone or in combination. While these molecules induce tumor regression and stimulate cytotoxic responses in mouse models of tumor development, results from early clinical trials are less impressive. In this review, we list the biological differences between human and mouse macrophages that help explain the different efficacy of antitumor strategies targeting TAMs between human and animal studies. Differences in the impact of survival and polarization factors and in the cytokines produced and markers expressed as well as the limitations of extrapolations based on in vitro models of TAM-like generation should be considered in order to improve the design and efficacy of antitumor drugs targeting TAMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.